Semaglutide, marketed as Ozempic, Wegovy, and Rybelsus, is a glucagon-like peptide-1 (GLP-1) receptor agonist used for type 2 diabetes management and weight loss
13 Treatment groups Experimental Treatment Placebo Group Part A Randomized 1:1 Part B Sema, high dose trevo, and gareto followed by high dose trevo Randomized 1:1:1:1:1:1:1:1 Part B Sema, high dose trevo, and garetosmab (gareto) followed by SC placebo Randomized 1:1:1:1:1:1:1:1 Part B Sema, high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1 Part B Sema, high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1 Part B Sema, moderate-high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1 Part B Sema, moderate-high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1 Part B Sema and SC placebo and IV placebo followed by high dose trevogrumab (trevo) Randomized 1:1:1:1:1:1:1:1 Part B Semaglutide (sema) and subcutaneous (SC) placebo and intravenous (IV) placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1 Part C Sema and SC moderate dose trevo Randomized 1:2:2 Part C Sema and SC low dose trevo Randomized 1:2:2 Part C Sema and SC placebo Randomized 1:2:2 Part A Randomized 1:1 Find a Clinic Near You Who Is Running the Clinical Trial
Pre-filled commercial pens usually do not require this math
What Sets Ivm Health Apart Our membership model allows us to offer unique benefits that set us apart: Quality and Safety Commitment: We only select FDA-inspected, state-regulated compounding pharmacies that meet regulatory board standards for quality and safety to fulfill our compounded GLP-1 medication prescriptions
